Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer
12 Julio 2023 - 3:15PM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of hallux valgus
(commonly known as bunions) through its Lapiplasty® 3D Bunion
Correction™ Procedure, today announced that Julie Dewey will join
the Company as Chief Communications and Investor Relations Officer,
effective July 17, 2023. In this new position, Ms. Dewey will lead
all aspects of Treace’s corporate communications and investor
relations engagement, with a focus on expanding the company’s
outreach with the investment community and broadening the Company’s
relationships with key stakeholders, including current and
potential investors, securities analysts, and the media.
“Julie is a talented and well-respected corporate communications
leader who we are thrilled to welcome to Treace,” said John T.
Treace, CEO, Founder and Board Member of Treace. “With a wealth of
industry experience, demonstrated track record of success and
outstanding reputation within the investment community, Julie is
ideally suited to communicate the Company’s unique value
proposition as our pioneering 3D bunion correction and related
midfoot solutions continue to gain momentum.”
“Throughout my career, I’ve always admired and been attracted to
organizations at the forefront of their industry, and from that
vantage point, there could not be a more exciting company to join
right now than Treace,” said Julie Dewey. “I look forward to
working with John and the extended Treace leadership team to
execute on the Company’s growth strategy, build Treace’s position
with current and future investors and deliver a best-in-class
experience for the investment community and key stakeholders.”
Ms. Dewey joins Treace with extensive experience in the
medical device industry, including senior leadership roles in
Investor Relations, Corporate Communications and Marketing, most
recently as Chief Corporate Communications and IR Officer for Nevro
Corp. Prior to Nevro, she was Senior Vice President and Chief
Communications Officer of Wright Medical Group, N.V., a leading
orthopaedic company focused on extremities and biologics, which was
acquired by Stryker. While at Wright, she built a world-class
investor relations program that was the highest ranked small-mid
cap medical device IR program by Institutional Investor for a
record five consecutive years. Earlier in her career, Ms. Dewey
held investor relations and marketing positions at ev3 Inc.
(acquired by Covidien/Medtronic), Kyphon Inc. (acquired by
Medtronic) and Thoratec Corporation (acquired by St. Jude/Abbott).
Ms. Dewey received a B.S. degree in business administration from
the University of Southern California and an M.B.A. from Pepperdine
University.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical fact
are forward-looking statements, including, but not limited to the
Company’s expectations regarding continuing momentum of its 3D
bunion correction and related midfoot solutions and the Company’s
plans for its investor relations program. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results and other events may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. Factors that could cause actual results
or other events to differ materially from those contemplated in
this press release can be found in the Risk Factors section of
Treace’s public filings with the Securities and Exchange Commission
(SEC), including its Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the SEC on March 8, 2023 and its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023,
filed with the SEC on May 9, 2023. Because forward-looking
statements are inherently subject to risks and uncertainties, you
should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements speak only as of
their date and, except to the extent required by law, the Company
undertakes no obligation to update these statements, whether as a
result of any new information, future developments or
otherwise.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company
with the goal of advancing the standard of care for the surgical
management of bunion and related midfoot deformities. Bunions are
complex 3-dimensional deformities that originate from an unstable
joint in the middle of the foot and affect approximately 65 million
Americans, of which Treace estimates 1.1 million are annual
surgical candidates. Treace has pioneered and patented the
Lapiplasty® 3D Bunion Correction™ System – a combination of
instruments, implants, and surgical methods designed to surgically
correct all 3 planes of the bunion deformity and secure the
unstable joint, addressing the root cause of the bunion and helping
patients get back to their active lifestyles. Treace expanded its
offering with the Adductoplasty® Midfoot Correction System,
designed for reproducible surgical correction of the midfoot to
provide further support to hallux valgus patients. For more
information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn,
Twitter, Facebook and Instagram.
Contacts:
Treace Medical ConceptsMark L. HairChief
Financial Officermhair@treace.net(904) 373-5940
Investors: Gilmartin GroupLynn
Lewis or Vivian CervantesIR@treace.net
Treace Medical Concepts (NASDAQ:TMCI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Treace Medical Concepts (NASDAQ:TMCI)
Gráfica de Acción Histórica
De May 2023 a May 2024